Iter-4360dd15-0122-transcript
第 122 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 erratum abstract investigator-assessed PFS original corrected sentence version"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0120-transcript", "tags": "iteration transcript", "modified": "20260424220420000", "preview": "!! 第 120 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 erratum investigator assessed PFS abstract metadata\"}) → call list_recent({\"n\":6}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0120-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424220420000\", \"preview\": \"!! 第 120 轮执行轨"}, {"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹 → call list_recent({"n":6})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0121-reflection", "modified": "20260424220536000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424220536000", "tags": "pinned focus"}, {"title": "更正只改被点名的那一句", "modified": "20260424220536000", "tags": "lesson evidence-chain erratum verification"}, {"title": "Iter-4360dd15-0121-transcript", "modified": "20260424220528000", "tags": "iteration transcript"}, {"title": "BOLERO-2 erratum scope: subgroup wording only, PFS numerics unchanged", "modified": "20260424220522000", "tags": "fact 4360dd15 clinical-trials erratum evidence-chain"}, {"title": "Iter-4360dd15-0120-reflection", "modified": "20260424220425000", "tags": "iteration reflection"}]}
→ call read_note({"title":"NEXT_FOCUS"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0121）\n\n逐字对照原文摘要与 erratum 修订句，确认可引用文本应以哪一个版本为准并锁定最终表述。"}
→ call web_search({"limit":5,"query":"BOLERO-2 erratum abstract subgroup wording original abstract PMC 22149876 erratum"})
【tool:web_search】
{"ok": true, "query": "BOLERO-2 erratum abstract subgroup wording original abstract PMC 22149876 erratum", "results": [{"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "snippet": "In the Abstract , patients with disease recurrence during or within 12 months of completion of adjuvant therapy are grouped with other patient subgroups as being \"prospectively defined\". This subgroup was not included within the prospectively defined patient subgroups for the BOLERO-2 trial."}, {"title": "PDF Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s12325-014-0150-8.pdf", "snippet": "The incorrect sentence in the abstract is: Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2 months, respectively; hazard ratio = 0.45 (95% confidence interval 0.38-0.54); log-rank P\0.0001 ..."}, {"title": "(PDF) Erratum to: Everolimus Plus Exemestane in ... - ResearchGate", "url": "https://www.researchgate.net/publication/258044358_Erratum_to_Everolimus_Plus_Exemestane_in_Postmenopausal_Patients_with_HR_Breast_Cancer_BOLERO-2_Final_Progression-Free_Survival_Analysis", "snippet": "In the phase III BOLERO-2 trial, exemestane plus everolimus was compared to exemestane plus placebo i
→ call web_fetch({"max_chars":7000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3838177/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3838177/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "A Novel Role for Keratin 17 in Coordinating Oncogenic Transformation and Cellular Adhesion in Ewing Sarcoma - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Mol Cell Biol . 2013 Nov;33(22):4448–4460. doi: 10.1128/MCB.00241-13 Search in PMC Search in PubMed View in NLM Catalog Add to search A Novel Role for Keratin 17 in Coordinating Oncogenic Transformation and Cellular Adhesion in Ewing Sarcoma Savita Sankar Savita Sankar Department of Oncological Sciences, Huntsman Cancer Ins
→ call web_search({"limit":10,"query":"BOLERO-2 final progression-free survival analysis PMC original abstract PMC PMID erratum abstract sentence"})
【tool:web_search】
{"ok": true, "query": "BOLERO-2 final progression-free survival analysis PMC original abstract PMC PMID erratum abstract sentence", "results": [{"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}, {"title": "Using quality-adjusted progression-free survival as an outcome measure ...", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461432/", "snippet": "Abstract The aim of this study is to estimate the quality-adjusted progression-free survival (QAPFS) as an effectiveness measure for the treatment arms of the BOLERO-2 trial."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://www.researchgate.net/publication/275428244_Abstract_P6-04-02_Final_progression-free_survival_analysis_of_BOLERO-2_a_phase_III_trial_of_everolimus_for_postmenopausal_women_with_advanced_breast_cancer", "snippet": "The final analysis of the phase-III BOLERO-2 trial revealed a mean progression-free survival (PFS) of 11 months under t
→ call web_search({"limit":8,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "ABSTRACT Introduction: positive (HR?) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy . Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III tria [ abstract ]."}, {"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [ abstract ]."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population. Intro
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
→ call web_search({"limit":8,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" PMC full text abstract"})
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" PMC full text abstract", "results": [{"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR + advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall ..."}, {"title": "Efficacy and safety of everolimus plus exemestane in postmenopausal ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6587781/", "snippet": "Keywords: estrogen receptor‐positive, HER2‐negative, advanced breast cancer, everolimus, exemestane Short abstract What's new? Current treatment guidelines for HR+, HER2- advanced breast cancer support continued endocrine therapy after progression on first‐line treatment, including the use of everolimus and exemestane combined."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everol
→ call web_fetch({"max_chars":10000,"url":"https://europepmc.org/article/MED/24158787"})
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/24158787", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call write_note({"tags":["fact","knowledge","4360dd15","clinical-trials","erratum","evidence-chain"],"text":"!! 结论\n对于 BOLERO-2 这篇文章，若要引用摘要中的最终可用文本，应以 PMC4713958 所给出的 correct sentence 为准，而不是原始摘要句。\n\n!! 逐字对照结果\n原始摘要句在 “all prospectively defined subgroups” 后面列出：\n- “including patients with visceral metastases, patients with recurrence during or within 12 months of completion of adjuvant therapy, and ir)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_abstract_should_cite_erratum-corrected_subgroup_wording.tid", "title": "BOLERO-2 abstract should cite erratum-corrected subgroup wording"}
【assistant】
本轮已完成“原文摘要 vs erratum 修订句”的逐字对照，并锁定可引用版本：
- **应采用 erratum 修订后的摘要句**
- 被删除的表述是原句中的：
- “patients with recurrence during or within 12 months of completion of adjuvant therapy”
- 保留的分组表述是：
- “including patients with visceral metastases, and irrespective of age”
- **PFS 数值段落未被改动**，仍可沿用原摘要/正文中的数值部分
我已将这条结论沉淀到记忆：**BOLERO-2 abstract should cite erratum-corrected subgroup wording**。
<NEXT_FOCUS>把 BOLERO-2 原始摘要句与 erratum 修订句做成可直接复用的“引用模板”，区分“该怎么写”和“哪些地方必须附 erratum 说明”。</NEXT_FOCUS>
```